Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00431964 |
|
Recruitment Status :
Completed
First Posted : February 6, 2007
Results First Posted : August 19, 2015
Last Update Posted : August 19, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cystic Fibrosis | Drug: azithromycin 250 mg tablets Drug: placebo tablets | Phase 4 |
Azithromycin is an antibiotic that has been shown to improve lung function in patients with cystic fibrosis (CF) whose lungs are infected with a bacterium called Pseudomonas aeruginosa. Scientists are not sure how azithromycin works in cystic fibrosis. It does not appear to work by killing the bacteria Pseudomonas aeruginosa, but it may make these bacteria and other bacteria less damaging to the lungs by reducing their ability to attach to the lining of the lung, or by reducing the bacteria's ability to make substances that damage the lungs of patients with cystic fibrosis. Azithromycin may also work directly on the cells in the lungs to improve lung function. This could occur by reducing inflammation (swelling) in the lungs, and/or making the mucus less sticky, or by affecting the salt channel that doesn't function correctly in CF. If azithromycin works in one or more of these ways; it may also be effective in improving lung function in cystic fibrosis patients who are not infected with Pseudomonas aeruginosa.
We are conducting this research study to examine the safety, effect on lung function and frequency of symptoms relating to cystic fibrosis during 24 weeks of treatment with the antibiotic azithromycin. This study is designed to determine if patients with cystic fibrosis whose lungs are not infected with the bacteria Pseudomonas aeruginosa will benefit from 24 weeks of treatment with the antibiotic azithromycin. Benefit will be determined as having better pulmonary function tests and getting sick less often compared to a placebo (sugar pill). This study is also designed to determine if azithromycin is safe when administered for 24 weeks to cystic fibrosis patients not infected with Pseudomonas aeruginosa. By doing this study, we hope to learn more about CF and improve the way in which we treat it.
Comparison: Three times weekly azithromycin tablets added to standard care, compared to three times weekly placebo tablets added to standard care.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 263 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Multi-center, Multi-national, Randomized, Placebo-Controlled Trial of Azithromycin in Subjects With Cystic Fibrosis 6-18 Years Old, Culture Negative for Pseudomonas Aeruginosa |
| Study Start Date : | February 2007 |
| Actual Primary Completion Date : | July 2009 |
| Actual Study Completion Date : | November 2009 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Active
azithromycin 250 mg tablets
|
Drug: azithromycin 250 mg tablets
Other Name: Zithromax |
|
Placebo Comparator: Placebo
placebo tablets (matched to active drug in appearance)
|
Drug: placebo tablets
Other Name: inactive pill |
- Change in FEV1 From Baseline to End of Treatment at Day 168 [ Time Frame: change from baseline to day 168 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 6 Years to 18 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female, 6-18 years of age at enrollment
- Confirmed diagnosis of CF
- Written informed consent (and assent when applicable)
- Clinically stable at enrollment as assessed by the site investigator
- FEV1 % predicted > 50%
- Ability to comply with medication use, study visits, and study procedures
- Ability to swallow a 250 mg tablet
Exclusion Criteria:
- Weight less than 18.0 kg
- Respiratory culture positive for P. aeruginosa, NTM, or B. cepacia complex within 1 year or at screening, or AFB positive at screening
- Allergy to macrolide antibiotics
- Use of macrolide antibiotics (e.g., azithromycin, clarithromycin) within 60 days of screening
- Use of systemic corticosteroids or intravenous or oral antibiotics within 14 days of screening
- Initiation of high dose ibuprofen, Pulmozyme®, hypertonic saline or aerosolized antibiotics within 30 days of screening
- Chronic therapy with drugs known to have rare but serious interactions with azithromycin: amiodarone, digoxin, disopyramide, lovastatin, pimozide, rifabutin, and nelfinavir
- Investigational drug use within 30 days of screening
- Laboratory abnormalities (creatinine, liver function or neutropenia) at screening and confirmed at follow-up testing prior to randomization
- History of biliary cirrhosis, portal hypertension, or splenomegaly, or splenomegaly on physical exam
- History of ventricular arrhythmia
- Other major organ dysfunction, excluding pancreatic dysfunction
- History of lung transplantation or currently on lung transplant list
- Relative decrease in FEV1 % predicted ≥ 20% between the screening and enrollment visit
- Positive serum pregnancy test at screening
- Pregnant, breastfeeding, or if post-menarche female, unwilling to practice birth control during participation in the study
- History of alcohol, illicit drug or medication abuse within 1 year of screening in the judgment of the site investigator
- Presence of a condition or abnormality that in the opinion of the site investigator would compromise the safety of the subject or the quality of the data
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00431964
Show 40 study locations
| Principal Investigator: | Lisa Saiman, MD, MPH | Columbia University | |
| Principal Investigator: | Michael Anstead, MD | University of Kentucky | |
| Principal Investigator: | Felix Ratjen, MD | The Hospital for Sick Children, Toronto, Ontario | |
| Principal Investigator: | Larry Lands, MD | Montreal Children's Hospital of the MUHC |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | CF Therapeutics Development Network Coordinating Center |
| ClinicalTrials.gov Identifier: | NCT00431964 |
| Other Study ID Numbers: |
AZ0004 |
| First Posted: | February 6, 2007 Key Record Dates |
| Results First Posted: | August 19, 2015 |
| Last Update Posted: | August 19, 2015 |
| Last Verified: | July 2015 |
|
azithromycin, Zithromax |
|
Cystic Fibrosis Fibrosis Pathologic Processes Pancreatic Diseases Digestive System Diseases Lung Diseases |
Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Azithromycin Anti-Bacterial Agents Anti-Infective Agents |